Head and Neck Cancer Trial, Recruiting NCT04564989 Sponsor: UNC Lineberger Comprehensive Cancer Center Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT04564989
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People with a specific stage of cancer in the throat (back of mouth/tonsil area) or from an unknown starting point in the head and neck, based on a standard staging system used by doctors (confirm with trial site)
  • People whose cancer has been confirmed by a tissue sample (biopsy) as a type called squamous cell carcinoma, located in the oropharynx (back of the throat) or with no identified primary site
  • People who have not had any previous cancer treatment
  • People with no signs that the cancer has spread to distant parts of the body
  • People whose cancer tests strongly positive for a protein called p16, which is measured in the lab from the biopsy sample
  • People who are planned to receive full, active cancer treatment (not just palliative or symptom management)
  • People who are in good general health and able to carry out normal daily activities with little or no limitation (as rated by a standard medical scale)
  • People who are able to follow the treatment plan and attend all required follow-up appointments
  • People who have given written consent to participate in the study before it begins

Who may not be able to join:

  • People who have previously received radiation therapy to the head or neck area
  • People who have a prior history of head or neck cancer
  • People whose pre-treatment tissue sample is not sufficient for the genetic analysis required by the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Wendell Yarbrough, MD, UNC Chapel Hill

Phone: 919-966-4432

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
UNC Lineberger Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
19 November 2020
Est. completion
1 November 2033

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Recurrence of OPSCC; Progression-free survival; Positive Predictive Value; Negative Predictive Value; Quality of Life questionnaire

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov